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Abstract: Background: Diagnostic performance of positron emission tomography using white blood
cells labeled with fluorine-18-fluorodeoxyglucose (18F-FDG-WBC PET or PET/CT) in patients with
suspicious infectious diseases has been evaluated in several studies; however, there is no consensus
about the diagnostic accuracy of this method. Therefore, a systematic review and meta-analysis
was carried out on this topic. Methods: A comprehensive computer literature search screening
PubMed/MEDLINE, Embase and Cochrane library databases through March 2019 was performed.
Pooled sensitivity, specificity, positive and negative likelihood ratios (LR+ and LR−), and diagnostic
odds ratio (DOR) of 18F-FDG-WBC PET or PET/CT in patients with infectious diseases were calculated.
Results: Eight studies on the use of 18F-FDG-WBC PET or PET/CT in suspicious infectious diseases
were discussed in the systematic review. The meta-analysis of seven studies (236 patients) provided
these pooled results on a per patient-based analysis: sensitivity was 86.3% [95% confidence interval
(95%CI) 75–92.9%], specificity 92% (95%CI 79.8–97.1%), LR+ 6.6 (95%CI: 3.1–14.1), LR− 0.2 (95%CI:
0.12–0.33), DOR 43.5 (95%CI: 12.2–155). A statistically significant heterogeneity was not detected.
Conclusions: Despite limited literature data, 18F-FDG-WBC PET or PET/CT demonstrated a good
diagnostic accuracy for the diagnosis of infectious diseases; nevertheless, larger studies are needed.
Keywords: PET; infection; 18F-FDG; leukocytes; white blood cells; meta-analysis
1. Introduction
Infectious diseases are a frequent cause of morbidity and mortality worldwide [1]. Early and
accurate diagnosis of infectious diseases can be difficult and time-consuming, whereas a delayed
diagnosis can be life-threatening. Accurate and early detection and localization of infectious diseases
is crucial for patient management and treatment, as well as for the cost containment [2,3].
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Clinical history, physical examination and various laboratory tests are performed in patients
with suspicious infection [2,3]. Several imaging methods can be used for localization of infectious
foci. The recent development of molecular imaging methods has enabled an improved diagnosis of
infectious diseases: Molecular imaging methods may detect infection and inflammation in an early
phase before the appearance of morphological changes [3–6]. To this regard, several radiolabeled
molecular probes are currently available for imaging of infectious diseases, including both non-specific
agents as fluorine-18-fluorodeoxyglucose (18F-FDG), a radiolabeled glucose analogue that accumulates
similarly in infection, sterile inflammation, and tumor lesions, and more targeted probes that seek to
differentiate infection from sterile inflammation [3–6].
Hybrid 18F-FDG positron emission tomography/computed tomography (PET/CT) may be used to
evaluate patients with suspicious infection and inflammation, due to the increased 18F-FDG uptake in
inflammatory cells, based on their high glycolytic metabolism. This imaging technique can identify the
source of infection or inflammation before morphological changes on conventional anatomical imaging
techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI), but it cannot
differentiate infection from sterile inflammation [7].
Planar scintigraphy or single photon emission computed tomography (SPECT) with autologous
radiolabeled white blood cells (WBC) are more specific molecular imaging modalities for diagnosis of
infection [5,6]. The main mechanisms of uptake of radiolabeled WBC at the site of infection are cellular
migration and target-specific localization: in fact, radiolabeled WBC localize to infected areas via
chemotaxis and diapedesis. In vitro labeling of WBC is a rigorous process that requires the following
steps: isolation of WBC from the patient’s blood, separation of WBC from plasma, WBC labeling and
suspension in plasma, and reinjection of radiolabeled WBC [5].
The relatively limited spatial resolution of SPECT compared to PET has led some researchers
to perform the ex-vivo labeling of WBC with 18F-FDG for PET/CT imaging of infectious diseases
(18F-FDG-WBC PET/CT) with initial promising results [3,6,7]. Therefore, we aimed to perform a
systematic review and bivariate meta-analysis about the diagnostic performance of 18F-FDG-WBC PET
or PET/CT in patients with suspicious infectious diseases to add evidence-based data in this setting [8].
2. Methods
This systematic review and meta-analysis was written according to the “Preferred Reporting
Items for a Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies” (PRISMA-DTA
statement), a guideline which describes the items required for reporting in systematic reviews and
meta-analyses of diagnostic accuracy studies [9].
2.1. Search Strategy
The co-authors performed a comprehensive computer literature search of PubMed/MEDLINE,
Cochrane library and Embase databases to find relevant published studies on the diagnostic accuracy
of 18F-FDG-WBC PET or PET/CT in patients with suspicious infectious diseases.
This search algorithm based on a combination of terms was created and used: (A) “FDG” OR
“fluorodeoxyglucose” AND (B) “label*” AND (C) “leukocyte*” OR “leucocyte*” OR “white blood” OR
“granulocyte*”. No beginning date limit nor language restrictions were used. The literature search
was updated until 26 March 2019. References of the retrieved articles were also screened to search for
possible additional articles.
2.2. Study Selection
Studies assessing the diagnostic performance of 18F-FDG-WBC PET or PET/CT in patients
with suspicious infectious diseases were eligible for inclusion in the qualitative (systematic review)
and quantitative analysis (meta-analysis). The exclusion criteria for the systematic review were:
(a) articles not within the field of interest; (b) editorials or letters, review articles, comments, conference
proceedings; and (c) case reports. If studies with possible patient data overlap were found, only the
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article with more complete information was included in the meta-analysis, whereas all of them were
included in the systematic review.
All the co-authors independently screened the abstracts of the retrieved articles, applying the
predefined inclusion and exclusion criteria. Subsequently, the researchers independently reviewed
the full-text of the selected articles to assess their eligibility for inclusion. Disagreements were solved
through a consensus meeting among all co-authors.
2.3. Data Extraction
For each selected study, information was collected on basic study characteristics (authors, year of
publication, country, study design), patient characteristics (type and number of patients evaluated, age
and sex ratio), technical details (type of hybrid imaging used, activity used for WBC labeling, WBC
labeling efficiency, injected activity, time interval between radiotracer injection and image acquisition,
image analysis and other imaging methods performed for comparison), and data on diagnostic accuracy
on a per patient-based analysis (including true positive and true negative findings, false positive and
false negative findings, sensitivity, specificity, positive and negative predictive values and accuracy).
2.4. Quality Assessment
The quality of the studies included in this systematic review was critically appraised using the
revised “Quality Assessment of Diagnostic Accuracy Studies” tool (QUADAS-2) [10]. QUADAS-2
includes four domains (patient selection, index test, reference standard, and flow and timing) and each
domain was assessed in terms of risk of bias, and the first three domains were also assessed in terms of
concerns regarding applicability [10].
2.5. Statistical Analysis
Sensitivity and specificity, positive and negative likelihood ratios (LR+ and LR−) and diagnostic
odds ratio (DOR) of visual analysis of 18F-FDG-WBC PET or PET/CT in patients with suspicious
infectious diseases were obtained from individual studies on a per patient-based analysis. A bivariate
random-effects model was used for statistical pooling of data about sensitivity and specificity.
This statistical approach takes into account any correlation that may exist between sensitivity and
specificity [11]. A random-effects model was used for statistical pooling of LR+, LR− and DOR.
Pooled data were presented with 95% confidence intervals (95%CI) and displayed using forest plots.
Heterogeneity has been estimated by using the I-square index (I2) [12]. Publication bias was assessed
through the Egger’s test [13].
Statistical analyses were performed using OpenMeta[Analyst]®software (version 0.1503) funded
by the Agency for Healthcare Research and Quality (AHRQ) (Rockville, Maryland, United States).
3. Results
3.1. Literature Search
Literature search results are summarized in Figure 1.
A total of 160 records were identified through the comprehensive computer literature search of
PubMed/MEDLINE, Cochrane library and Embase databases. Screening 160 abstracts, 148 records were
excluded: 130 because they were not in the field of interest, 11 as editorials, reviews or letters, seven as
case reports. Twelve articles were selected and retrieved in full-text. No additional records were found
screening the references of these articles, whereas four articles were excluded after the analysis of the
full text. Therefore, eight articles were included in the qualitative analysis (systematic review) [14–21].
One article was excluded from the meta-analysis for possible patient data overlap [16]. Overall, seven
articles (236 patients with suspicious infectious diseases) were included in the quantitative analysis
(meta-analysis) [14,15,17–21]. The characteristics of the studies included in the systematic review
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are presented in Tables 1 and 2. Diagnostic accuracy data from these articles are showed in Table 3,
whereas the overall quality assessment of the studies is reported in Figure 2.Diagnostics 2019, 9, x FOR PEER REVIEW 4 of 12 
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Table 1. Basic study and patient characteristics.
Authors Year Country Study Design Type of Patients Evaluated No. of Patients Performing18F-FDG-WBC PET or PET/CT
Mean Age
(Years) % Male
Kim et al. [14] 2018 South Korea prospectivesingle center
Patients with autosomal dominant
polycystic kidney disease and suspicious
cyst infection
19 54 (38–73) 37%
Rastogi et al. [15] 2016 India prospectivesingle center
Patients with Charcot’s neuroarthropathy
and suspicious diabetic foot osteomyelitis 23 57.9 ± 7.8 96%
Kwon et al. [16] 2016 South Korea prospectivesingle center
Patients with autosomal dominant
polycystic kidney disease and suspicious
cyst infection
17 53 (38–73) 35%
Yilmaz et al. [17] 2015 Turkey prospectivesingle center
Patients with suspicious musculoskeletal,
vascular or soft-tissue infection 49 55.7 (16–89) 55%
Bhattacharya et al. [18] 2014 India prospectivesingle center
Patients with suspicious infected fluid
collections in acute pancreatitis 41 41 ± 11.5 68%
Aksoy et al. [19] 2014 Turkey prospectivesingle center
Patients with suspicious prosthetic joint
infection 46 61 ± 12.2 22%
Dumarey et al. [20] 2006 Belgium prospectivesingle center Patients with suspicious infectious diseases 21 56 (24–84) 62%
Rini et al. [21] 2006 USA prospectivesingle center Patients with suspicious infectious diseases 43 59 (32–86) 47%
Legend: 18F-FDG-WBC = white blood cells labeled with fluorine-18 fluorodeoxyglucose; CT = computed tomography; NA = not available; PET = positron emission tomography.
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Table 2. Technical aspects of the included studies.
Authors Hybrid Imaging Modality Activity Used forWBC Labeling
Mean WBC Labeling
Efficiency (%) Injected Activity Image Analysis
Other Imaging Modalities Performed
for Comparison
Kim et al. [14] PET/CT (low-dose CT) 740 MBq NR NR visual MRI or CT
Rastogi et al. [15] PET/CT (low-dose CT) NR 73 ± 28 NR visual and semi-quantitative(SUVmax)
18F-fluoride PET/CT and MRI
Kwon et al. [16] PET/CT (low-dose CT) 740 MBq NR 189 ± 107 MBq visual MRI or CT
Yilmaz et al. [17] PET/CT (low-dose CT) 740–925 MBq 70 ± 13 70-433 MBq visual and semi-quantitative(SUVmax)
18F-FDG PET/CT
Bhattacharya et al. [18] PET/CT (low-dose orcontrast enhanced CT) 314.5–555 MBq 81 ± 17 262.7 ± 70.3 MBq
visual and semi-quantitative
(SUVmax)
-
Aksoy et al. [19] PET/CT (low-dose CT) 740–925 MBq 75 ± 17 296–703 MBq visual and semi-quantitative(SUVmax)
18F-FDG PET/CT
Dumarey et al. [20] PET/CT (low-dose CT) 740 MBq 75 ± 21 303 ± 111 MBq visual and semi-quantitative(SUVmax) -
Rini et al. [21] No (PET only) 660–740 MBq 72 ± 8 196–315 MBq visual 111In-WBC scintigraphy
Legend: 18F-FDG = Fluorine-18 Fluorodeoxyglucose; CT = computed tomography; 111In = Indium-111; MBq = MegaBecquerel; min = minutes; MRI = magnetic resonance imaging; NR =
not reported; PET/CT = positron emission tomography/computed tomography; SUVmax = maximal standardized uptake value; WBC = white blood cells.
Table 3. Diagnostic accuracy data of 18F-FDG WBC PET or PET/CT in the included studies on a per patient-based analysis.
Authors True Positive False Negative False Positive True Negative Sensitivity Specificity PPV NPV Accuracy
Kim et al. [14] 9 5 2 3 64.3% 60% 81.8% 37.5% 63.2%
Rastogi et al. [15] 10 2 0 11 83.3% 100% 100% 84.6% 91.3%
Kwon et al. [16] * NA NA NA NA 85.7% 87.5% 85.7% 87.5% NA
Yilmaz et al. [17] 20 4 3 22 83.3% 88% 87% 84.6% 85.7%
Bhattacharya et al. [18] 10 0 0 25 100% 100% 100% 100% 100%
Aksoy et al. [19] 13 1 1 31 92.9% 96.9% 92.9% 96.9% 95.7%
Dumarey et al. [20] 12 2 1 6 85.7% 85.7% 92.3% 75% 85.7%
Rini et al. [21] 13 2 5 23 86.7% 82.1% 72.2% 92% 83.7%
Legend: NA = not available; * = excluded from the meta-analysis for possible data overlap; NPV = negative predictive value; PPV = positive predictive value.
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3.2. Qualitative Analysis (Systematic Review)
3.2.1. Basic Study and Patient Characteristics
Screening the selected databases, eight articles evaluating the diagnostic performance of
18F-FDG-WBC PET or PET/CT in patients wih suspicious infectious diseases were selected
(Table 1) [14–21]. All the selected articles were prospective single-center studies published from
2006 to 2018 by research groups of different countries from Europe, Asia and America. The mean age
of patients included in these studies ranged from 41 to 61 years and the percentage of male patients
(sex ratio) ranged from 22% to 96%.
3.2.2. Technical Aspects
Technical details about 18F-FDG-WBC PET or PET/CT in the included studies are summarized in
Table 2. Hybrid PET/CT was performed in 87.5% of the studies, without contrast-enhanced CT in the
majority of cases. Mean WBC labeling efficiency ranged from 70% to 81%.
The injected activity and the time interval between injection and PET acquisition were quite
different among the studies. The analysis of PET and PET/CT images was performed by using
qualitative criteria (visual analysis) in all the studies. Some authors have used visual scores for
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PET images, comparing the activity in suspicious lesions and in background regions. Additional
semi-quantitative criteria, i.e., through the calculation of the maximal standardized uptake values
(SUVmax), were used in 62% of studies. At visual analysis all the areas of focal increased radiotracer
uptake greater than the surrounding tissue and not judged as physiological activity were considered to
be abnormal. Normal physiologic biodistribution of 18F-FDG-WBC includes the reticuloendothelial
system (liver, spleen and bone marrow). Minimal radiotracer activity may be detected in brain,
myocardium and urinary bladder (due to 18F-FDG eluted from radiolabeled WBC). Compared to
18F-FDG PET, no physiological activity is usually demonstrated in bowel, kidneys or ureters by using
18F-FDG-WBC PET [14–21].
Histopathological/microbiological results and/or clinical/imaging/biochemical work-up and
follow-up were used as reference standard in the included studies.
3.2.3. Main Findings
No adverse effects were seen in any of the patients after the 18F-FDG-WBC injection [14–21].
Radiation exposure to the staff performing the labeling procedure varied from 4 to 10 µSv for each
patient [18]. When measured, the 18F-FDG-WBC viability ranged from 97% to >99% [18,21].
In most of the included studies a good diagnostic performance of 18F-FDG-WBC PET or PET/CT
in patients wih suspicious infection (including musculoskeletal, vascular or soft-tissue infections) was
reported (Table 3).
False negative findings of 18F-FDG-WBC PET or PET/CT were due to poor host immune reaction,
low virulence or chronic infections, vertebral osteomyelitis, infections in site of physiological radiotracer
uptake, prior antibiotic therapy or immunosuppressant drugs administration. False positive findings
of 18F-FDG-WBC PET or PET/CT were due to hemorrhagic lesions, some cases of aseptic/sterile
inflammation, recent surgery or eluition of 18F-FDG from radiolabeled WBC over time [14–21].
Compared to conventional imaging methods (CT and MRI) and 18F-FDG PET/CT, a higher
diagnostic performance was found using 18F-FDG-WBC PET or PET/CT in patients with suspicious
infection [14–17,19]. One study found comparable results in terms of diagnostic accuracy among
18F-FDG-WBC PET and scintigraphy using WBC labeled with Indium-111-oxine (111In-WBC) [21].
3.3. Quantitative Analysis (Meta-Analysis)
Seven prospective studies including 236 patients with suspicious infectious diseases were selected
for the bivariate meta-analysis [14,15,17–21]. Results of the meta-analysis are presented in Figures 3–5.
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The sensitivity of 18F-FDG-WBC PET or PET/CT in patients with suspicious infectious diseases
ranged from 64.3.8% to 100%, with a pooled estimate of 86.3% (95%CI: 75–92.9%). The specificity
of 18F-FDG-WBC PET o PET/CT in patients with suspicious in ectious diseases ranged from 60%
to 100%, with a pooled es imate of 92% (95%CI: 79.8–97.1%). The pooled LR+, LR− nd DOR wer
6.6 (95%CI: 3.1–14.1), 0.2 (95%CI: 0.12–0.33), and 43.5 (95%CI: 12.2–155), respectively (Figures 3–5).
No significant statistical heterogen ity among the studies was fo nd for all the metrics evaluated
(I2 < 50%). No significant publication bias was detected by the Egger’s test (p > 0.1).
4. Discussion
Osman and Danpure first described the in vitro labeling of WBC with 18F-FDG, showing that
87% of 18F-FDG is associated with labeling of granulocytes [22]. Subsequently, several studies have
evaluated the diagnostic performance of 18F-FDG-WBC PET or PET/CT in different types of infectious
diseases [14–21], but these studies have limited power due to the small number of patients enrolled.
Therefore, we have pooled data reported in the published studies through a bivariate meta-analysis
to derive more robust estimates on the diagnostic performance of 18F-FDG-WBC PET or PET/CT in
this setting.
Overall, despite the relatively limited data, our systematic review and bivariate meta-analysis
demonstrated a good diagnostic performance of 18F-FDG-WBC PET or PET/CT in patients with
suspicious infectious diseases without significant adverse effects. To this regard, possible false
negative findings (i.e., due to poor host immune reaction, low virulence or chronic pattern of disease,
vertebral osteomyelitis, infections in site of physiological radiotracer uptake, prior antibiotic therapy or
immunosuppressant drugs administration) and false positive findings (i.e., due to hemorrhagic lesions,
some cases of aseptic/sterile inflammation, recent surgery or eluition of 18F-FDG from radiolabeled WBC
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over time) should be taken into account when nuclear medicine physicians interpret 18F-FDG-WBC
PET or PET/CT images [14–21].
About the comparison of 18F-FDG-WBC PET or PET/CT with other imaging modalities in patients
with suspicious infectious diseases, a higher diagnostic performance was found using 18F-FDG-WBC
PET/CT compared to conventional imaging methods (CT or MRI) and 18F-FDG PET/CT [14–17,19].
The normal biodistribution of 18F-FDG includes the brain and the genitourinary tract and variably
high activity in the myocardium, bone marrow, gastro-intestinal tract and liver. 18F-FDG PET/CT may
have a reduced performance for the detection of infection in these sites [7]. Conversely, the physiological
uptake of 18F-FDG-WBC essentially occurs within the reticuloendothelial system. The absence of
gastrointestinal and renal uptake and the faint brain and myocardial uptake makes 18F-FDG-WBC
PET/CT a suitable imaging method for the assessment of intra-abdominal, renal, cardiac and cerebral
infectious diseases [14–21]. Another difference between 18F-FDG-WBC PET/CT and 18F-FDG PET/CT
relates to the different cellular types involved in the signal detected in infected sites. 18F-FDG reveals
different types of inflammatory cells, including macrophages, whereas 18F-FDG-WBC essentially
reveals active diapedesis of granulocytes through chemotactic processes [20,23], and this could explain
the higher diagnostic performance obtained by using 18F-FDG-WBC PET/CT compared to 18F-FDG
PET/CT in patients with suspicious infectious diseases [17,19].
Only one study compared 18F-FDG-WBC PET and 111In-WBC scintigraphy in patients with
suspicious infectious diseases reporting a similar diagnostic performance of these imaging methods [21].
However, further considerations should be added to this regard. The labeling efficiency of
18F-FDG-WBC is variable and significantly lower than that of WBC radiolabeled with gamma-emitting
tracers [15,17–21]; although not examined in detail, the leukocyte glucose transporter expression,
the serum glucose levels, and the presence of intrinsic proteins have been thought to affect the
labeling efficiency of 18F-FDG-WBC [3]. Nevertheless, the relative low labeling efficiency seems to
not affect the diagnostic accuracy of 18F-FDG-WBC PET or PET/CT in detecting infectious diseases.
On the other hand, the mean cell viability of 18F-FDG-WBC was very high and comparable to that
of radiolabelled WBC used for scintigraphy [18,21]; thus, the 18F-FDG labeling procedure does not
affect the WBC viability. Another factor that should be considered is the short physical half-life of 18F
which excludes imaging at 24 h after radiotracer injection (as usually performed for radiolabeled WBC
scintigraphy); the WBC labeling and loading time may also have an impact due to the fast radiotracer
decay. Some advantages of 18F-FDG-WBC PET/CT compared to radiolabelled WBC scintigraphy or
SPECT are the better image quality and resolution and the reduced imaging time [21]. Dosimetry of
18F-FDG-WBC PET for activities of 225–315 MBq was found to be comparable to results with 111In-WBC
scintigraphy [24].
Although the short half-life of 18F excludes imaging at 24 h after radiotracer injection (which is
known to increase the specificity of radiolabeled WBC scintigraphy), a high sensitivity and specificity
for infection was found in our pooled analysis on 18F-FDG-WBC PET or PET/CT; the better resolution of
PET imaging compared to planar scintigraphy and SPECT may have contributed to the high sensitivity
and the high level of anatomic detail provided by the co-registered CT images may have contributed
to the high specificity [20].
Contrast enhancement could further improve the diagnostic performance of 18F-FDG-WBC
PET/CT for detection of infection, in particular for visceral localizations, but this should be better
evaluated in further studies [18,20]. Moreover, the use of semi-quantitative criteria of interpretation of
18F-FDG-WBC PET/CT (by using SUVmax thresholds) seems to be not sufficiently accurate to make a
differential diagnosis between infectious and non-infectious conditions, but semi-quantitative analysis
can be used as an adjunct tool to visual analysis for PET interpretation, even if a possible effect of cell
division on the SUVmax within the imaging time frame cannot be excluded [17].
Different imaging times after 18F-FDG-WBC injection were adopted in the selected studies [14–21]:
delayed image acquisition may improve the contrast between infectious foci and background, but might
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increase the possibility of 18F-FDG decay and detachment from WBCs [16]; additional studies are
needed to identify the optimal 18F-FDG-WBC PET/CT imaging protocol.
Diagnostic accuracy of an imaging test is not a measure of clinical effectiveness and high diagnostic
performance does not necessarily result in improved patient outcomes. Other factors beyond the
diagnostic performance should influence the choice of an imaging modality in patients with suspicious
infectious disease (i.e., availability, radiation dose, safety, examination time, legal, organization,
economic aspects). Overall, our systematic review and meta-analysis demonstrated a good diagnostic
performance of 18F-FDG-WBC PET/CT in patients with suspicious infectious diseases, but larger
prospective and multicenter studies on this topic are needed, in particular, more comparison studies
with radiolabeled WBC scintigraphy are warranted. There are some drawbacks of 18F-FDG-WBC
PET/CT that should be underlined, including the relatively long time for WBC labeling, the need for
high 18F-FDG activities for labeling, variable labeling efficiency, risk of contamination by direct contact
with blood products and radiation exposure [3,6,7,19]. Furthermore, the possibility of an increased risk
of lymphoid malignancies associated with the administration of 18F-FDG-WBC is a very controversial
subject that needs further investigation [25]. Lastly, there are still insufficient in vitro data on putative
elution of 18F-FDG from radiolabeled WBC over time [7].
Some limitations and biases of our meta-analysis should be taken into account. First of all, a limited
number of studies were available for the meta-analysis. Moreover, as a composite reference standard
was used in most of the studies a possible verification bias could not be excluded. Furthermore, based
on the information provided in the studies selected for the meta analysis, a selection bias could be
present. Heterogeneity among studies (i.e., due to baseline differences among the patients included,
diversity in methodological aspects, and different study quality) may represent a potential source of
bias in a meta-analysis [11]. We have not detected a statistically significant heterogeneity among the
included studies in our meta-analysis, although the significant differences about the patient population
evaluated and the technical details in the included studies.
5. Conclusions
Based on available literature data, 18F-FDG-WBC PET or PET/CT seem to demonstrate a good
diagnostic performance in detecting infectious diseases.
The literature on this topic is still limited and further investigations on 18F-FDG-WBC PET/CT
in patients with suspicious infectious diseases are warranted. Based on available data, this imaging
method should not be considered as standard clinical practice, but it could be used in a research setting.
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